Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Epstein

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Blood|May 27, 2006
The molecular classification of multiple myelomaFenghuang Zhan, Yongsheng Huang, Simona Colla, et al.
Blood|April 23, 2013
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myelomaSaad Z Usmani, Jeffrey Sawyer, Adam Rosenthal, et al.
Theranostics|August 2, 2019
Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?Leo Rasche, Manoj Kumar, Grant Gershner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2007
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implicationsRonald Walker, Bart Barlogie, Jeffrey Haessler, et al.
British Journal of Haematology|June 27, 2007
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3Bart Barlogie, Elias Anaissie, Frits van Rhee, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2014
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsSusann Szmania, Natalia Lapteva, Tarun Garg, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Blood|April 23, 2017
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myelomaLeo Rasche, Edgardo Angtuaco, James E McDonald, et al.
British Journal of Haematology|August 31, 2006
Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie, Guido J Tricot, Frits van Rhee, et al.
Haematologica|March 16, 2012
Highly activated and expanded natural killer cells for multiple myeloma immunotherapyTarun K Garg, Susann M Szmania, Junaid A Khan, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Blood|May 27, 2006
The molecular classification of multiple myelomaFenghuang Zhan, Yongsheng Huang, Simona Colla, et al.
Blood|April 23, 2013
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myelomaSaad Z Usmani, Jeffrey Sawyer, Adam Rosenthal, et al.
Theranostics|August 2, 2019
Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?Leo Rasche, Manoj Kumar, Grant Gershner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2007
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implicationsRonald Walker, Bart Barlogie, Jeffrey Haessler, et al.
British Journal of Haematology|June 27, 2007
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3Bart Barlogie, Elias Anaissie, Frits van Rhee, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2014
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsSusann Szmania, Natalia Lapteva, Tarun Garg, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Blood|April 23, 2017
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myelomaLeo Rasche, Edgardo Angtuaco, James E McDonald, et al.
British Journal of Haematology|August 31, 2006
Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie, Guido J Tricot, Frits van Rhee, et al.
Haematologica|March 16, 2012
Highly activated and expanded natural killer cells for multiple myeloma immunotherapyTarun K Garg, Susann M Szmania, Junaid A Khan, et al.
Pageof 9